4.91
price down icon0.41%   -0.02
after-market After Hours: 4.91
loading
Agenus Inc stock is traded at $4.91, with a volume of 857.74K. It is down -0.41% in the last 24 hours and up +28.53% over the past month. Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$4.93
Open:
$5
24h Volume:
857.74K
Relative Volume:
0.88
Market Cap:
$147.23M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0714
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
+9.84%
1M Performance:
+28.53%
6M Performance:
+74.73%
1Y Performance:
-65.45%
1-Day Range:
Value
$4.81
$5.02
1-Week Range:
Value
$4.465
$5.18
52-Week Range:
Value
$1.38
$18.74

Agenus Inc Stock (AGEN) Company Profile

Name
Name
Agenus Inc
Name
Phone
781-674-4410
Name
Address
3 FORBES ROAD, LEXINGTON, MA
Name
Employee
316
Name
Twitter
@Agenus_Bio
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
AGEN's Discussions on Twitter

Compare AGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGEN
Agenus Inc
4.91 147.23M 160.43M -227.64M -170.79M -68.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Agenus Inc Stock (AGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-04-25 Upgrade H.C. Wainwright Neutral → Buy
Jul-19-24 Downgrade Robert W. Baird Outperform → Neutral
Jul-18-24 Downgrade H.C. Wainwright Buy → Neutral
Jul-18-24 Downgrade William Blair Outperform → Mkt Perform
Jun-06-23 Initiated Robert W. Baird Outperform
Feb-28-23 Resumed H.C. Wainwright Buy
Sep-28-22 Initiated SMBC Nikko Outperform
Dec-16-21 Initiated H.C. Wainwright Buy
Nov-19-19 Resumed B. Riley FBR Buy
Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy
Dec-16-15 Initiated Jefferies Buy
Oct-27-15 Downgrade Maxim Group Buy → Hold
Jul-27-15 Reiterated MLV & Co Buy
Jun-11-15 Initiated Oppenheimer Outperform
Jan-12-15 Reiterated Maxim Group Buy
Jan-09-15 Reiterated MLV & Co Buy
Jan-09-15 Reiterated Maxim Group Buy
Dec-19-14 Reiterated Maxim Group Buy
May-08-14 Reiterated Maxim Group Buy
Mar-14-14 Reiterated MLV & Co Buy
Oct-08-13 Reiterated Maxim Group Buy
Jan-05-12 Initiated William Blair Outperform
Dec-01-11 Initiated Global Hunter Securities Buy
View All

Agenus Inc Stock (AGEN) Latest News

pulisher
Jun 18, 2025

# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Agenus, Noetik Enter Research Collaboration - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan

Jun 17, 2025
pulisher
Jun 15, 2025

10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.

Jun 13, 2025
pulisher
Jun 12, 2025

Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com

Jun 12, 2025
pulisher
Jun 11, 2025

Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 10, 2025

H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Agenus Announces Virtual Annual Shareholders Meeting - New Castle News

Jun 10, 2025
pulisher
Jun 10, 2025

How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Research Analysts Issue Forecasts for Agenus FY2027 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

HC Wainwright Forecasts Agenus’ Q3 Earnings (NASDAQ:AGEN) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues

Jun 06, 2025
pulisher
Jun 05, 2025

Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL - Medical Dialogues

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US - 뉴스와이어

Jun 05, 2025
pulisher
Jun 04, 2025

Agenus Announces Strategic Collaboration with Zydus - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus IncSigns Partnership Agreements With Zydus Lifesciences - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangAgenus (NASDAQ:AGEN) - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus Shares Rise After Upgrade From HC Wainwright - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades Agenus stock on strategic collaboration - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades Agenus stock on strategic collaboration By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Mai - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Maintained | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Upgraded to 'Buy' by HC Wainwright & Co. | AGEN St - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades Agenus (AGEN) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Stock Price Target Increased by Baird | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus and Zydus sign agreements for botensilimab and balstilimab - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus gets rights for next gen I-O platforms from Agenus - The Pharma Letter

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | A - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus signs deal with Agenus for next-gen cancer immunotherapies - Healthcare Radius

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to enter global biologics CDMO business to accelerate development of innovative therapies - Pharmabiz.com

Jun 04, 2025
pulisher
Jun 04, 2025

Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to enter global biologics CDMO business Plans to acquire Agenus’ U.S. manufacturing facilitiesto accelerate development of innovative therapies - APN News

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business - Indian Pharma Post

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market - Express Pharma

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies - StreetInsider

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus inks $141M deal with Zydus for cancer drugs, facilities By Investing.com - Investing.com South Africa

Jun 04, 2025

Agenus Inc Stock (AGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):